Statistics on Biotechnology Use  
Results by fields of operation
Total Sectors. Biotechnology indicators by execution sector. 
Unidades: 

,Total 2021,Companies,P.A.,Higher Education,PNPI,
Companies that perform R+D in Biotechnology,1.547,1.348,120,66,13,
%Companies according to biotechnology used: Genetic code,38,31,87,5,89,4,46,2,
%Companies according to biotechnology used: Functional Companies,44,8,38,4,88,3,93,9,53,8,
%Companies according to biotechnology used: Cellular and tissue culturing and engineering,28,8,21,7,73,3,86,4,61,5,
%Companies according to biotechnology used: Bioprocesses,53,50,3,58,3,93,9,69,2,
%Companies according to biotechnology used: Sub-cellular organisms,14,8,8,2,53,3,74,2,38,5,
%Companies according to biotechnology used: Bio-computing,30,7,24,1,73,3,87,9,30,8,
%Companies according to biotechnology used: Nanobiotechnology,17,7,11,8,54,2,72,7,15,4,
%Companies according to biotechnology used: Other,14,9,16,4,3,3,7,6,0,
Companies in which biotechnology activities are:  Main and/or exclusive,705,661,31,3,10,
Companies in which biotechnology activities are: A secondary line of business,276,188,41,46,1,
Companies in which biotechnology activities are: A tool necessary for production,567,500,48,17,2,
%Companies by field(s) of ultimate application of biotechnology use: Human Health,50,5,45,8,76,7,95,5,69,2,
%Companies by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture,17,8,15,3,17,5,69,7,23,1,
%Companies by field(s) of ultimate application of biotechnology use: Food products,32,9,31,5,24,2,81,8,7,7,
%Companies by field(s) of ultimate application of biotechnology use: Agriculture and forest production,25,7,23,7,22,5,72,7,23,1,
%Companies by field(s) of ultimate application of biotechnology use: Environment,19,15,5,25,8,78,8,7,7,
%Companies by field(s) of ultimate application of biotechnology use: Industry,15,8,13,4,14,2,68,2,7,7,
Personnel in R&D in biotechnology (no. of persons),47.144,15.744,15.418,15.757,225,
Personnel in R&D in biotechnology (no. of persons): Research personnel,30.818,8.380,9.510,12.778,150,
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel,16.326,7.364,5.908,2.979,75,
Personnel in R&D in biotechnology (no. of persons). Women,26.646,8.725,9.684,8.101,136,
Personnel in R&D in biotechnology (no. of persons). Women. Research personnel,16.551,4.521,5.637,6.314,79,
Personnel in R&D in biotechnology (no. of persons). Women. Technical and auxiliary personnel,10.095,4.204,4.047,1.787,57,
Personnel in R&D in biotechnology (FTE),32.896,3,11.523,2,11.271,7,9.934,5,166,9,
Personnel in R&D in biotechnology (FTE): Research personnel,20.944,7,6.341,6,6.454,3,8.036,112,8,
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel,11.951,6,5.181,6,4.817,4,1.898,5,54,1,
Personnel in R&D in biotechnology (FTE). Women,18.965,5,6.552,7,7.077,3,5.228,107,5,
Personnel in R&D in biotechnology (FTE). Women: Research personnel,11.346,3.464,4,3.786,8,4.032,9,61,9,
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel,7.619,5,3.088,3,3.290,5,1.195,1,45,6,
Internal expenditure on R&D (thousands of euros),2.269.251,1.037.887,716.877,500.703,13.783,
1) By nature of the expense: Current expenses,2.086.468,939.471,672.607,461.216,13.174,
1.1) Remuneration to research personnel,872.151,321.525,252.863,293.131,4.630,
1.2) Remuneration to technicians and auxiliary personnel,384.242,194.656,128.640,59.408,1.538,
1.3) Other current expenses,830.076,423.290,291.103,108.677,7.006,
2) By nature of the expense: Capital expenses,182.782,98.416,44.270,39.487,610,
2.1) Land and buildings,20.257,10.150,2.712,7.373,23,
2.2) Equipment and instruments,144.096,72.538,40.235,30.775,549,
2.3) Acquisition of specific R+D software,8.151,5.713,1.102,1.303,33,
2.4) Otros productos de propiedad intelectual específicos para I+D,10.278,10.015,222,36,5,
1.1) By origin of the funds: Own funds,891.115,711.037,88.338,88.167,3.574,
1.2) By origin of the funds: From companies,247.985,121.595,97.993,25.096,3.301,
1.3) By origin of the funds: Public Administration funds,882.530,107.422,430.689,342.018,2.402,
1.4) By origin of the funds: From Universities,3.851,192,1.388,2.220,50,
1.5) By origin of the funds: From non profit private institutions,47.810,10.756,26.599,7.719,2.737,
1.6) By origin of the funds: Foreign funds,195.959,86.884,71.871,35.483,1.720,
Purchase of services R & D in Biotechnology to (thousands of euros),174.817,145.440,23.461,3.058,2.858,
Purchase of services R & D in Biotechnology to (thousands of euros): in Spain,123.416,95.870,21.807,3.035,2.704,
Purchase of services R & D in Biotechnology to (thousands of euros): Abroad,51.401,49.570,1.654,23,154,
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital,42,5,39,8,63,3,57,6,61,5,
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information,11,9,12,5,6,7,9,1,15,4,
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources,21,5,18,5,45,40,9,23,1,
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain,13,3,11,2,26,7,33,3,7,7,
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets,17,8,15,6,30,42,4,15,4,
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and marketing channels,18,5,16,5,27,5,39,4,30,8,
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception,15,6,16,1,10,12,1,30,8,
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements,40,1,40,40,37,9,61,5,
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost,54,4,53,9,58,3,57,6,61,5,
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting,21,5,21,5,24,2,18,2,23,1,
Notas:
'..'=data not available 

 '.'=numeric piece of data equal to zero not resulting from rounding 

 FTE: Full Time Equivalent 

 (*) Total calculated from the total number of companies with related activities  with Biotechnology and the total Companies from other sectors with activities  in R&D in Biotechnology
Fuente: National Statistics Institute